Description
Latin name
AFALAZA
Release form
lozenges. On 20 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. On 1, 2 or 5 blister strip packagings together with the instruction for medical application are placed in a pack from a cardboard.
Packaging
For 20 tablets in a blister strip packaging from a film of polyvinyl chloride or aluminum foil.
5 blister packs along with instructions for medical use are placed in a pack of cardboard.
Pharmacological action
Pharmacotherapeutic group
Prostate hyperplasia benign treatment.
ATX Codes G04CX.
Pharmacological properties of
Pharmacodynamics
It has been experimentally and clinically shown that antibodies to the prostate-specific antigen (PSA) affinity-purified modify the functional activity of endogenous PSA, altered with benign prostatic hyperplasia, which is accompanied by an increase in the regulatory effect of this antigen on the functional and metabolic processes in the tissue of the prostate gland, have a pronounced anti-inflammatory and decongestant effect.
Affinity-purified antibodies to endothelial NO synthase increase blood flow, including in the vessels of the penis and prostate gland, have a protective effect on endothelium (helps to reduce vascular reactivity, reduce vascular spasm and improve peripheral microcirculation). The combined use of the components in the complex preparation Afalase is accompanied by a synergistic effect: antibodies to endothelial NO synthase, due to endothelial protective effect and improved vascularization, enhance the antiproliferative and anti-inflammatory activity of antibodies to PSA. The synergistic effect is probably also due to non-specific mechanisms for enhancing intracellular signal transduction by dilutions of antibodies to endothelial NO synthase.
In patients with BPH, the drug, when used for 12 months, helps to reduce the volume of the prostate gland, improve urodynamics (decrease the volume of residual urine, increase the maximum speed of urine), significantly reduce the severity of dysuric disorders without affecting the PSA level.
The drug improves the quality of life of patients with benign prostatic hyperplasia (BPH).
The presence of a pronounced anti-inflammatory and decongestant effect in the drug has been experimentally shown. The drug helps to normalize the functional state of the prostate and lower urinary tract, improvement of urodynamic indicators (decrease in the volume of residual urine, increase in maximum urine speed), normalization of PSA level.
Pharmacokinetics
The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow us to evaluate the content of the active components of the drug Afalaza in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.
Indications
Benign prostatic hyperplasia.
Dysuric disorders (as part of complex therapy): frequent urination, difficulty urinating, pain and discomfort in the perineum.
Contraindications
Increased individual sensitivity to the components of the drug.
Use during pregnancy and lactation
The drug Afalaza is not intended for use in women.
Composition
Active substances: Antibodies to endothelial NO synthase affinity purified – 0.006 g *,
Antibodies to prostate-specific antigen affinity purified – 0.006 g *. Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.
* is applied to lactose monohydrate as a mixture of three active water-alcohol dilutions of a substance diluted in 10012, 10030, respectively 100200 times
Dosage and administration
Inside. 2 tablets, 2 times a day, in the morning and in the evening (keep in your mouth until completely dissolved – outside the meal).
In dysuric disorders, the drug is recommended to be taken within 16 weeks.
On the recommendation of a doctor for severe pain and dysuric disorders in the first 2-3 weeks of therapy, the drug is indicated up to 4 times a day.
To prevent prostate growth in patients with BPH and reduce the risk of disease progression, it is recommended to take the drug 2 times a day, morning and evening for 12 months.
Side effects
When using the drug for the indicated indications and at the indicated dosages, no side effects were detected.
Drug Interaction
There have been no incidents of incompatibility with other drugs.
overdose
In case of accidental overdose, dyspepsia may occur due to excipients included in the composition of the drug.
Storage conditions
In the dark place at a temperature of no higher than 25 ° C.
Keep out of the reach of children.
Expiration
3 years
Do not use after expiration date.
Deystvuyuschee substances
Homeopatycheskyy composition
pharmacy
without pharmacy
dosage form
dosage form
lozenges
Materia Medica Holding28 Russia Russia1919
